IPC Councilors play an essential role in the work of IPC. IPC Councilors serve in an advisory capacity and lend their global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives. They provide expert opinions on current psoriasis therapeutic and research-related issues, participate in round-table conferences, contribute to manuscripts submitted to top-tier journals, and present at important congresses around the world. Learn more about our global volunteer network by searching the Meet the Experts directory.
The IPC Board seeks colleagues who hold a position in a professional specialty relevant to IPC’s mission. The individual either manages the care of people with psoriasis or psoriatic arthritis or performs research relevant to psoriasis and its multiple comorbidities.
Councilor selection is based on demonstrated expertise and leadership in the field of psoriasis or one of its comorbidities. To be considered, candidates must meet at least three of the following criteria:
These criteria reflect IPC’s commitment to recognizing well-established individuals who have contributed substantially to the psoriasis field through research, education, clinical practice, and professional leadership.
Please note: Because IPC conducts its activities in English—including meetings, publications, and collaborative work—proficiency in English is required for all Councilors. This ensures full participation and effective communication across IPC’s global network.
Councilors wishing to remain active must participate in one IPC activity over two years.
Activities may include:
Candidates must:
The IPC Executive Team will screen each application and CV to confirm eligibility. If necessary, additional information will be requested to support your application. The IPC Membership Committee will review eligible applications and make recommendations to the IPC Board of Directors on a quarterly basis.
Final approval of candidacy for all IPC Councilors is at the discretion of the IPC Board of Directors.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
